Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS3731 safety study in healthy adults
NCT05691660Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAS3731 in Voiding dysfunction and underactive bladder (UAB) (3 cohorts), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Number and incidence rate of adverse events, Number and incidence rate of adverse drug reactions and 6 more. Started Jan 2023; status: completed.
02
Drugs
TAS3731
03
Conditions
Voiding dysfunctionunderactive bladder (UAB)
Beyond the preview
Go deeper on NCT05691660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691660.